Best GLP-1 After Failing Mounjaro: What to Try Next, Based on What Happened

There is no proven best GLP-1 after failing Mounjaro. Wegovy is a different medicine to discuss, including Wegovy HD when appropriate. Zepbound is still tirzepatide, not a stronger replacement. First, separate slow weight loss, a plateau, side effects, and loss of access. Each calls for a different review. ¹, ², ³, ⁴, ⁵

By The RX Index · Last verified: September 22, 2026 · U.S. prices checked at Ro, LillyDirect, NovoCare, and Sesame

The RX Index — Independent guidance for choosing your GLP-1 path.

Disclosure: Some links on this page are affiliate links, and each one is labeled "sponsored." If you start care through one, we may earn a commission at no cost to you. Every table, the worksheet, and the appointment script on this page can be used without clicking any of them. How we make money

This page is for you if:

• You've taken Mounjaro for months, followed your prescribed dose plan, and the scale barely moved. Or it moved, then stopped.
• You want an honest, FDA-approved next step, not another sales pitch.

Start elsewhere if: Mounjaro worked but cost or coverage took it away—use our best Mounjaro alternatives guide. If blood sugar is your main concern, start with your diabetes prescriber and our type 2 diabetes guide.

Get medical help now for severe belly pain that won't go away, trouble breathing, or swelling in your face or throat. Mounjaro's medication guide says to stop using it and call your healthcare provider right away for persistent severe belly pain. For trouble breathing or throat swelling, call 911. ⁶

Best GLP-1 after failing Mounjaro: the answer depends on what happened

The best next step after Mounjaro depends on how it failed. Poor weight loss calls for a treatment review, not an automatic switch to Wegovy HD. Cost or coverage may call for a better way to get tirzepatide. Blood sugar above target calls for a diabetes plan. ¹, ², ⁷, ⁸

Find your row below. Then jump to the part that fits you.

Notice that not every row leads to a new drug. We're not dodging your question. A proper review could save you from paying for a switch that solves the wrong problem.

That last part matters more than it sounds. In a Lilly trial analysis, 250 of 278 early slow responders—about 9 out of 10—reached at least 5% weight loss by week 72. These were adults without diabetes who took at least 75% of their assigned doses and had the required weight measurements. They had lost less than 5% at week 12. A slow start was not the end of their results. It does not give every slow responder a 90% chance of success. ⁹

So before you pay for anything new, take one minute to write down what happened. We'll show you how, and what to ask about next.

Explore my GLP-1 care options →

The RX Index's Find My GLP-1 Path tool. Use it to explore providers—not to decide your next dose or diagnose why Mounjaro fell short.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, your medical needs, whether you want a shot or a pill, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to explore your care options, then confirm the treatment, price, and coverage with the provider before choosing.

What we actually verified (September 22, 2026): public cash prices and terms on Ro, LillyDirect, NovoCare, and Sesame; current drug labels and FDA notices; the cited studies and manufacturer trial reports; and Ro's and Sesame's published billing and cancellation terms. What we did not do: sign up for or cancel Ro or Sesame, complete a pharmacy purchase, or treat any patient. See our full method ↓

Did Mounjaro really fail? Check these 4 things first

A slow start does not always mean Mounjaro will not help. Your dose history, time on treatment, side effects, and diabetes status all matter. The UK's NICE guidance calls for a review when someone loses less than 5% after 6 months at their highest tolerated dose—not an automatic stop, and not a rule to wait 6 months before asking for help. ⁹, ¹⁴, ⁷

Grab your real numbers. You'll use them again in the appointment script later.

1. How long have you been at your highest dose?

Mounjaro starts at 2.5 mg weekly, then increases to 5 mg after 4 weeks. Further increases are in 2.5 mg steps, only if needed, after at least 4 weeks at the current dose. The adult maximum is 15 mg. Reaching it on the fastest labeled schedule takes 20 weeks; reaching it is not a requirement for everyone. So "I've been on it 4 months" does not tell the whole story. ⁶

2. How much have you lost since your first dose?

Here's the math: (starting weight − current weight) ÷ starting weight × 100.

Example: 240 lb down to 228 lb is 12 ÷ 240 = 5%.

3. Do you have type 2 diabetes?

Compare yourself with a study group that also had diabetes. Average weight loss was lower in the tirzepatide diabetes trial than in the trial without diabetes. That does not mean you did something wrong. ¹⁵, ¹⁶

4. Did it stop working, or never start?

Losing 30 pounds and then stalling is a plateau. Losing almost nothing despite a sustained, tolerated treatment trial raises a different question. They lead to different next steps. ¹⁷, ⁷

What "working" looks like on tirzepatide

We pulled these from five trial analyses and one national guideline so you can compare yourself to the right group, not a TikTok highlight reel.

Here's the number we want you to sit with. In the diabetes trial, about 1 in 6 people on the top dose didn't reach 5% (100% minus 83%). If that's you, you're not broken. You're in a real, known group, and there are still next steps. ¹⁶

Try it: your Mounjaro review worksheet

Write these in your notes or on paper. You do not need to sign up for anything to use this worksheet.

This worksheet does not tell you to stop, keep taking, or change a medicine. It gives your prescriber the facts needed to review the plan.

What your answers mean:

• Recent dose changes or limited time on treatment? Ask whether your treatment exposure is enough to judge. Do not increase a dose or delay a side-effect review to reach an internet deadline. ⁶, ⁷
• Lost weight, then flat for 3+ months? Your medicine may now be doing its second job: holding the weight off. Read what happens if you switch before you change anything. ¹⁰, ¹¹
• 6+ months at your highest tolerated dose and under 5% lost? That meets NICE's review point. Keep reading. This page was built for you. ⁷

Use my numbers in the appointment message →

Is there a GLP-1 stronger than Mounjaro?

No approved medicine has been shown to be the best replacement after Mounjaro failed. In a head-to-head trial, tirzepatide produced 20.2% average weight loss versus 13.7% with semaglutide—but that trial used semaglutide up to 2.4 mg, not Wegovy HD 7.2 mg. It did not study rescue treatment after tirzepatide failure. ³

That's the hard truth. You were already on a heavyweight. So the real question isn't "what's stronger?" It's "what's different enough to give you a better shot?"

The After-Mounjaro Evidence Map

Average weight loss is only part of the story. We added the column that matters most for you: was this ever tested in people after tirzepatide failed?

These are different trials with different people. Treat them as ballparks, not a race. An analysis that assumes continued treatment uses a statistical model; it does not simply average only the people who stayed on the drug. The findings do not predict your next result.

Cash prices were checked September 22, 2026. Offer rules, prescribed dose, and fill timing matter. Telehealth membership, office visits, and other care costs are separate. Prices for an injection fill cover four weekly doses, not a full calendar month.

Retatrutide: real promise, not yet an approved medicine

Retatrutide acts on three hormone receptors—GIP, GLP-1, and glucagon—instead of tirzepatide's two. In Lilly's TRIUMPH-1 trial, people assigned to 12 mg had an estimated average 28.3% weight reduction over 80 weeks under the continued-treatment analysis. In TRIUMPH-2, the corresponding result in people with type 2 diabetes was 20.8%. These are Lilly-reported trial results, not results in Mounjaro nonresponders. ²⁶, ²⁵

It has a side effect to know about, too. About 12.5% of people on the top dose in TRIUMPH-1 reported altered skin sensation, like tingling or touch sensitivity, compared with 0.9% on placebo. ²⁶

Here's the part that matters today: retatrutide is not FDA-approved for prescribing or retail sale. Lilly plans to file its application in the first quarter of 2027; that is not an approval or launch date. The FDA says retatrutide cannot be used in compounding under federal law. It has also warned companies selling "research use only" GLP-1 products to consumers. We cover that more below. ²⁵, ²⁷

To explore legitimate research access, search ClinicalTrials.gov and check whether a listed study is recruiting and whether you meet its requirements.

CagriSema: the dose and trial population matter

CagriSema pairs semaglutide with cagrilintide, a drug that mimics the hormone amylin. In Novo Nordisk's REDEFINE 4 trial, it produced 23.0% average weight loss versus 25.5% for tirzepatide 15 mg, and it missed its goal of proving it was at least as good. Those percentages use the analysis assuming continued treatment. ²⁴

A September 21, 2026 update changes the broader comparison: Novo Nordisk reported 12.4% weight loss with CagriSema 1 mg/1 mg versus 9.1% with tirzepatide 5 mg at 60 weeks in REIMAGINE 5, a trial in adults with type 2 diabetes. That does not show it beat tirzepatide 15 mg or worked after Mounjaro failure. Different doses answer different questions. ²⁸

It's still waiting on the FDA. Track it on our CagriSema FDA approval status page. ²³, ²⁸

Can Wegovy work if Mounjaro didn't?

It might. Wegovy is a different drug: semaglutide acts on the GLP-1 receptor, while tirzepatide acts on GIP and GLP-1 receptors. One case report describes further weight loss after a switch, but no randomized trial has established Wegovy as a rescue treatment for Mounjaro nonresponders. ⁶, ², ⁴, ⁵

What Wegovy HD adds to the discussion

Wegovy HD is semaglutide at 7.2 mg, three times the old top dose. The FDA approved it on March 19, 2026. ¹⁸

• In the STEP UP trial, adults without diabetes had estimated average weight loss of 20.7%, assuming continued treatment; the result regardless of treatment adherence was 18.7%. About 1 in 3 lost 25% or more. ¹⁸
• In people with type 2 diabetes, the corresponding averages were 14.1% assuming continued treatment and 13.2% regardless of treatment adherence. ¹⁸

For context, tirzepatide 15 mg produced 14.7% average loss in its diabetes trial using the analysis regardless of treatment adherence. Different trials, so it's not a fair race. But it tells you something honest. If you have diabetes, HD is a different shot, not a guaranteed upgrade. ¹⁶, ¹⁸

The honest evidence gap

Here's what the available reports can—and cannot—tell us about switching after tirzepatide didn't work:

• One patient. A 2026 case report described a 40-year-old man whose weight went from 115 kg to 109.5 kg on tirzepatide, then to 92 kg after 6 months on semaglutide 2.4 mg. That is 20% below his original weight, not 20% lost after switching. The additional loss after the switch was about 16%: 17.5 ÷ 109.5 × 100. That's encouraging. It's also one person—and he did not take Wegovy HD. ⁴
• One large observational study that still could not settle the question. A July 2026 preprint analyzed 24,876 slow responders in telehealth records. Its findings about switching between drug classes were limited and inconclusive. It was not a randomized trial and had not been peer-reviewed. It does not establish a dependable tirzepatide-to-semaglutide rescue plan. ⁵

So if anyone tells you Wegovy is "proven" to work after Mounjaro, they're guessing. It's an option to discuss. It's not a promise.

The catch: you can't start on HD

Wegovy HD is only for adults who have handled Wegovy 2.4 mg for at least 4 weeks and need additional weight reduction. You have to work up to it under a prescriber's plan. ²

On the standard label schedule, Wegovy steps up through 0.25, 0.5, 1, 1.7, and 2.4 mg, with 4 weeks at each step. After those 20 weeks, the first HD dose could be at week 21, in the sixth four-week fill. Your prescriber may keep you at a dose longer or decide HD is not right for you. Do not use this cost example as your switching instructions. ²

What the Wegovy HD path costs—medication only:

Prices checked September 22, 2026 against NovoCare's published terms. The $199 offer covers two eligible 0.25 mg or 0.5 mg fills for people new to the applicable savings offer or NovoCare Pharmacy, through December 31, 2026. Check whether both fills qualify before budgeting. Without that offer, the same six fills total $2,144. This is a budget at the checked prices, not a guaranteed future quote. A telehealth membership, if you use one, is extra. Six four-week fills are not six calendar months. ¹⁹

"Isn't Wegovy gentler on my stomach?"

Not necessarily. In the SURMOUNT-5 head-to-head trial, 5.6% of people on semaglutide quit because of stomach side effects, versus 2.7% on tirzepatide. That comparison did not include Wegovy HD. ³

HD also has a dose-specific trade-off: its current label reports altered skin sensation in 22% of people on 7.2 mg versus 6% on 2.4 mg in the relevant trial. Higher-dose treatment is not just more weight loss with no extra downside. ²

If side effects were your problem, the pill section explains the options—but a pill is not automatically easier on your stomach.

Already tried Wegovy before Mounjaro?

If regular Wegovy didn't work for you and you have never used 7.2 mg, HD is a dose you have not tried. But ask your prescriber directly whether going back to semaglutide makes sense for you, or whether a full review is the better move.

Considering Wegovy? Explore Ro's program and treatment options → (sponsored)*

Ro lists Wegovy HD at $399 per four-week supply, the same medication price listed by NovoCare. Already have a prescriber who'll write it? You can buy it direct from NovoCare with no telehealth membership. Office visits and other care may still cost extra. ²⁹, ¹⁹

Will Zepbound work if Mounjaro didn't?

Changing to Zepbound does not change the active medicine: both products contain tirzepatide. Their approved uses and coverage can differ, but a brand switch alone does not address poor response to the same dose. Ask whether the proposed change solves an access problem or actually changes your treatment plan. ⁶, ¹

Here's a line we'd tape to every telehealth ad if we could: a new brand name or a new company doesn't make the same medicine stronger. If tirzepatide didn't work for you at 15 mg, Zepbound at 15 mg is tirzepatide at 15 mg. ⁶, ¹

In the U.S., Mounjaro is approved for type 2 diabetes and, under its current label, certain cardiovascular risk reduction in adults with type 2 diabetes. Zepbound is approved for weight management in eligible patients and for moderate-to-severe obstructive sleep apnea in adults with obesity—not every kind of sleep apnea. Mounjaro does not have a U.S. weight-management indication; using it for that purpose is off-label. ⁶, ¹

But if Mounjaro was working and you lost it to cost or insurance, Zepbound may be exactly what you need. Just watch the price trap:

Prices checked September 22, 2026. Zepbound prices above are per four-dose, 28-day supply. The higher-dose Lilly offer requires refilling within 45 days of the prior delivery or receipt, as the terms specify. Outside that offer, listed regular prices are $499 for 7.5 mg and $699 for 10–15 mg. Check the exact product and dose on your prescription. KwikPen requires pen needles; vials require needles and syringes, bought separately. ²², ³²

The useful comparison is the offer, not just the website name. Sesame's displayed higher-dose prices do not match Lilly's $449 offer. That does not prove a Sesame patient must pay more: ask whether your prescription can use the current manufacturer offer and which pharmacy will fill it.

For the full switch, see how to switch from Mounjaro to Zepbound and our best Mounjaro alternatives guide.

Was cost your real problem? Check your GLP-1 insurance coverage with Ro → (sponsored)*

Ro advertises a free insurance coverage check. A coverage result is not a prescription or a guarantee that a prior authorization will be approved. ²⁹

Could a GLP-1 pill be your next step?

A pill is worth discussing when injections are the problem or you need a plan to maintain weight already lost. Two FDA-approved daily pills for weight management are Foundayo and the Wegovy pill. Neither has been established as a rescue for people who did not respond to tirzepatide, and both can cause stomach side effects. ², ¹², ¹³, ¹⁰

Foundayo (orforglipron)

• Approved: April 1, 2026, by the FDA, for adults with obesity or overweight with a weight-related health problem. ¹²
• How you take it: once a day, any time, with or without food. It does not have Wegovy pill's fasting and water restrictions. ¹²
• Results: up to 12.4% average weight loss at the highest dose in ATTAIN-1 when assuming continued treatment; 11.2% in the analysis regardless of treatment adherence. ¹³
• Side effects: nausea hit about 29% to 36% of people across the doses studied, versus about 10% on placebo. 5.3% to 10.3% stopped because of adverse events, versus 2.7% on placebo. These are study results, not your personal risk estimate. ¹³
• Cash price: $149 at 0.8 mg; $149 at 2.5 mg; $199 at 5.5 mg; $299 at 9 mg. The top doses, 14.5 and 17.2 mg, cost $299 with the qualifying 45-day refill offer or $349 otherwise; the clock starts from delivery or receipt of the prior prescription. A supply is 30 tablets. ²⁰, ²¹

Which Foundayo prices expire? The reduced 2.5 mg and 5.5 mg prices run through December 31, 2026. Their listed regular prices are $199 and $299. Do not assume every dose's current price has the same expiration rule. ²¹

Wegovy pill (oral semaglutide)

• Results: about 14% average weight loss overall, or about 17% in an analysis assuming continued treatment. ²
• How you take it: in the morning on an empty stomach, with no more than 4 ounces of plain water. Wait at least 30 minutes before food, other drinks, or other oral medicines. ²
• Cash price: $149 at 1.5 mg, $199 at 4 mg, and $299 at 9 mg or 25 mg, per 30-day supply. ¹⁹

Where a pill fits after Mounjaro

Lilly's ATTAIN-MAINTAIN trial studied moving from high-dose injections to oral orforglipron. It was built to test keeping weight off, not rescuing non-response. We break down the numbers in the next section. People switching from tirzepatide to the pill kept much of their earlier loss on average, but not all of it. ¹⁰, ¹¹

Before choosing a pill, name the problem it would solve: the injection itself, the daily routine, access, or a maintenance plan. Changing the format is not proof that the medicine will work better or cause fewer side effects.

Want to compare daily pills? Explore Foundayo and oral GLP-1 options options on Ro → (sponsored)*

More detail: Foundayo cost without insurance · how to get the oral GLP-1 options online

Will you regain weight when you switch?

Some regain can happen, so plan a switch with your prescriber instead of leaving a treatment gap. In ATTAIN-MAINTAIN, people who moved from tirzepatide to orforglipron had an estimated average 5 kg—about 11 lb—of regain over 52 weeks. That study involved people who had already lost weight, not people whose original treatment never helped. ¹⁰, ¹¹

The fear is real: "I've worked so hard. I don't want to lose it." Fair. Here's what the maintenance trials actually show:

These are modeled group averages under continued-treatment analyses, not a claim that every person kept or regained that amount. ATTAIN-MAINTAIN enrolled people who completed SURMOUNT-5; its main analysis focused on the subgroup whose weight had plateaued. Not every participant had reached a plateau. ¹⁰, ¹¹, ³³

Use matching time periods: at 24 weeks after tirzepatide, the reported regain was 2.6 kg with orforglipron versus 9.1 kg with placebo. Do not compare a 52-week pill result with a 24-week placebo result as though they covered the same time. ³³

The takeaway: if Mounjaro is holding weight off for you, it's still doing a job. Any switch should be a planned handoff with a start date, not a gap.

Do not combine two GLP-1 treatments on your own. The product labels do not recommend taking Wegovy or Zepbound with another GLP-1 medicine. Ask for written instructions naming your last dose of the old medicine and the first dose of the new one. ¹, ²

Does type 2 diabetes change the answer?

Yes. Weight loss in the tirzepatide trial with type 2 diabetes was lower on average than in the trial without diabetes. And if your A1C is the real problem, the next step depends on your whole diabetes plan—not just swapping one GLP-1 for another. ¹⁵, ¹⁶, ⁸

Mounjaro is FDA-approved to improve blood sugar in adults and children 10 and older with type 2 diabetes. Its August 2026 label also includes reducing major cardiovascular events in adults with type 2 diabetes at high risk for those events. This page's dose and switching discussion is for adults. ⁶

Here's the comparison using diabetes studies only:

Read that table twice if you have diabetes. These were separate studies, not a direct comparison of all six options. None tells you which drug will work after Mounjaro fell short. That's a reason to protect what's working and get a full review, not to jump.

If your blood sugar is the problem: the American Diabetes Association's 2026 guidance calls for a plan based on your blood sugar, weight goals, other conditions, side effects, and cost. Adding basal—long-acting—insulin is one option when more glucose lowering is needed; it is not the automatic answer for every person taking Mounjaro. The ADA does not recommend adding a DPP-4 inhibitor, such as Januvia, to a GLP-1 or dual GIP/GLP-1 medicine because it adds no meaningful glucose-lowering benefit. ⁸

If your blood sugar improved but your weight didn't: Mounjaro may still be doing its approved job. Talk to the clinician who manages your diabetes before you stop it. More here: best GLP-1 for type 2 diabetes.

Tried the top dose and nothing worked? What a full review can add

If you've spent 6 or more months on your highest tolerated dose and lost less than 5%, it's time for a bigger review, not just another prescription. You can ask for that review sooner when results, side effects, or cost are a problem. A clinician can consider other medicines, health conditions, non-GLP-1 treatments, surgery assessment, or clinical trials. ⁷, ⁸, ³⁵

Deep breath. This is the group that needs the most honesty, so here it is: there's no proven "next GLP-1" for you yet. But you have more options than another GLP-1 swap.

What a real review should cover

Bring these questions to the visit:

• Have I truly had a fair trial, counting missed doses and breaks?
• Could any of my other medicines, or another health condition, be working against my weight loss?
• Would a non-GLP-1 weight-loss medicine make sense for me?
• Do I meet the criteria for a weight-loss surgery evaluation?
• Is there a clinical trial I could join?

Also ask someone to check how you use and store your medicine. Bring the product name, prescribed dose, and any device or supply problem. That lets the clinician separate a treatment-response problem from a problem getting or taking the intended medicine. ⁶

Other FDA-approved weight-loss medicines exist

GLP-1s aren't the only option. Other FDA-approved weight-loss medicines include Contrave (naltrexone/bupropion) and orlistat. Phentermine and Qsymia are controlled substances, meaning they have extra prescribing rules, and some telehealth programs, including Sesame, don't prescribe them. ³⁰, ³⁵

A different medicine is not an invitation to build your own combination. Ask whether the plan replaces tirzepatide or adds something to it, what evidence supports that choice, and how side effects will be checked. ¹, ⁸

Why a new set of eyes can help

After one drug didn't work, the most useful thing is often a clinician who looks at your whole history, your labs, and every medicine you take. That's the case for picking your own clinician.

Before booking, ask one direct question: "Do you review people who have already tried tirzepatide, including options beyond another GLP-1?" A profile or subscription price alone does not answer that.

Want to choose who reviews your case? Compare clinicians on Sesame → (sponsored)*

Sesame lets you choose a provider from its list. Program lab work at Quest is included in most states, and plans start at $59 a month on an annual plan. Medication is extra. Details and billing terms are in our provider comparison below. ³⁰

What should you avoid when Mounjaro isn't working?

Don't stack two GLP-1s, don't push past Mounjaro's 15 mg adult maximum on your own, and don't buy "research use only" retatrutide online. The FDA says retatrutide cannot legally be used in compounding, and it has warned companies selling research-labeled GLP-1s directly to consumers. ⁶, ¹, ², ²⁷

When you're frustrated, the gray market starts to sound reasonable. Here's why it isn't:

• "Custom" doses above 15 mg. Fifteen milligrams weekly is the highest FDA-approved adult Mounjaro dose. A seller offering more has not found an approved Mounjaro upgrade. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. ⁶, ²⁷
• "Research" retatrutide. A research label is not a safe path to treatment. FDA has warned about sellers marketing GLP-1 products to consumers with dosing instructions while labeling them for research or not for human use. ²⁷
• Stacking drugs. Do not take Mounjaro with Wegovy, Zepbound, Foundayo, or another GLP-1 as a self-made combination. The relevant approved labels do not recommend combining these treatments. ¹, ², ¹²

What the FDA's report numbers mean: as of May 31, 2026, FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Those are reports, not confirmed counts of harm caused by the products. They are not all overdose reports and do not establish a side-effect rate. FDA separately describes problems involving dosing errors and doses or escalation schedules beyond approved labeling. ²⁷

A compounded drug is not a stronger version of Mounjaro. It's a different, unapproved product. Read more: compounded GLP-1 vs. name brand.

Before starting another treatment, check the safety basics

Tell the prescriber about past serious reactions, severe stomach-emptying problems, pregnancy or pregnancy plans, and every medicine you take. These GLP-1 treatments have thyroid-tumor warnings and must not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Weight-loss treatment is not used during pregnancy. Read the medication guide for the specific drug, not just the price page. ⁶, ¹, ², ¹²

Side effects are not a reason to wait for the six-month mark. Persistent vomiting, inability to keep fluids down, or severe pain needs medical advice promptly. Trouble breathing or throat swelling is an emergency. ⁶, ²

Where to get your next step: Ro vs. Sesame vs. your own doctor

You may not need a new program: your current prescriber can review a Wegovy treatment plan, a pill, or other options. Our fit-based view is that Ro suits readers exploring its listed branded treatments, while Sesame suits readers who want to choose a clinician. Neither has demonstrated better results specifically for Mounjaro nonresponders. Both list program fees separately from branded medication costs. ²⁹, ³⁰

Honestly? Start with the doctor you already have. If they'll review your history and write the next prescription, you can buy direct from NovoCare (Wegovy) or LillyDirect (Zepbound, Foundayo) with no membership at all. That does not make office visits or lab work free. Telehealth earns its fee when your doctor won't engage, insurance is a fight, or you want a fresh set of eyes. ¹⁹, ²², ²⁰

The review scores cover company-wide customer experiences. They are not scores for treatment after Mounjaro, proof of clinical quality, or personal outcome predictions.

Read the payment schedule before choosing the lowest price

Ro: $74 × 12 is $888 for a prepaid 12-month membership term, before medication. The lower monthly equivalent comes with an upfront commitment. Do not mistake it for a $74 cancel-anytime monthly plan. ²⁹, ³⁶

Sesame: $59 × 12 is $708 for a prepaid annual plan, before medication. Its program page describes the $99 option as renewing every 28 days, while its general membership terms describe same-date monthly billing. Confirm the schedule shown at checkout. At a 28-day cadence, 13 payments of $99 cover 364 days and total $1,287—not 12 payments. ³⁰, ³⁷

Canceling a prepaid Sesame plan: its published multi-month policy says used months, including partial months, are repriced at the standard month-to-month rate before any remaining balance is refunded. Depending on how much you used, there may be no refund. Its separate three-hour cancellation rule applies to virtual visits; it is not a blanket promise to refund an annual membership. ³⁷

Ask for four numbers before paying: the charge today, the next renewal charge, the medication price at your prescribed dose, and the amount you would get back if you stopped early.

Ro: a fit for exploring its FDA-approved treatment options

The one thing Ro doesn't do. Ro does NOT carry Mounjaro. If staying on the Mounjaro brand is your priority, your current prescriber or a clinician who offers it is a better place to start; Sesame lists it. Ro does offer Ozempic, so it would be wrong to say Ro skips all diabetes drugs. ²⁹, ³⁰, ⁴⁰

For the alternatives covered here, Ro lists Wegovy HD, Foundayo, the Wegovy pill, and Zepbound, along with published cash prices and insurance support. That gives you a way to explore those options without pretending a new provider makes the medicine stronger. ²⁹

What Ro reviewers say, in their own words:

"Very simple procedure to get started. Excited to start the program" — Donna, Trustpilot, September 14, 2026. ⁴¹

"It was easy to sign up. And the feedback was fast." — Audrey, Trustpilot, September 13, 2026. ⁴¹

These are individual service experiences, not evidence of medical results or what most people should expect. We verified the published text, not the reviewers' identities or health histories.

The review split: 65% of Ro's Trustpilot reviews are 5 stars and 22% are 1 star. ³⁸

The bill to know about: The $39 covers month one of membership, not medication. After that it's $149 a month, unless you prepay a year at $74 a month. So plan for it. Ro's terms say membership can keep renewing even when you do not request or receive medication. To stop the next charge, cancel at least 48 hours before renewal. ²⁹, ³⁶

The care limit to know about: Ro's terms describe routine weight-loss care, not a replacement for a specialist or emergency service. Choose based on the review you need, not just the drug menu. ³⁶

Does that fit what you need? Explore Ro's $39 introductory offer → (sponsored)*

The offer advertises a refund if you are not eligible. Medication is extra; review the ongoing fee before enrolling. ²⁹

Sesame: a fit if you want to pick who reviews your case

Sesame is a marketplace. You read provider profiles, pick one, and meet by video. The program includes messaging and, in most states, lab work. The trade-off is that care depends on who you choose, and providers set their own prices, so some charge more. ³⁰

Read the clinician's profile, ask about experience with poor tirzepatide response, and confirm the billing schedule and refund terms before signing up. Sesame's terms do not promise a refund because a clinician declines to prescribe or you disagree with the medical decision. ³⁷

Does a review with a clinician you choose sound right? Compare Sesame's providers and plans → (sponsored)*

More on programs: best GLP-1 online programs · Ro vs. LillyDirect · Ro GLP-1 reviews

What to say at your next appointment (copy this)

Bring your dose history, your weight change, and one clear question: what will be different next time? A good next plan names the drug, the dose, the reason for the change, and the date you'll check whether it's working.

Don't leave with only a new script and no plan. Walk in with this instead. Copy it, fill in the blanks, and send it through your patient portal before the visit.

Hi [name]. Before we change anything, I'd like to review my Mounjaro results.

• Started: [date], at [dose] mg
• Highest dose: [____] mg, reached on [date]
• Weight: [start] → [now] ([____]% lost)
• Missed doses or breaks: [none / when]
• Side effects: [list]
• Type 2 diabetes: [yes / no]. Last A1C: [____]

My main concern is [little weight loss / weight stopped / side effects / cost]. My questions: 1. Have I had a fair trial at my dose? 2. If we switch, what are we switching to, and why? 3. How will we know in 3 to 6 months if it's working, and do I need an earlier check? 4. What will it cost me, and is there a cheaper approved option? 5. What are the exact last-dose and first-dose instructions, and which symptoms mean I should contact you sooner?

Also bring: a list of every medicine and supplement you take, your weight log (even a rough one), and your insurance card.

You can copy the message above into your notes or patient portal. No purchase is needed to use it.

Need a different care provider? Explore my GLP-1 options →

How we built this guide

We separated four kinds of claims: FDA approvals and labels, clinical trial results, provider-stated prices and terms, and our own editorial judgments. We also checked what each study actually tested, whether that was general weight loss, slow early response, or keeping weight off after a switch. Those are different questions, so we didn't turn them into a single "best drug" ranking.

What we added: the After-Mounjaro Evidence Map separates rescue evidence from general weight-loss and maintenance studies. The price tables separate drug cost from program fees and identify refill and billing conditions. The worksheet turns those facts into questions you can take to an appointment. These are our comparisons and calculations from cited sources—not new clinical research.

How we judge providers: we use the RX Index Score, which rates providers on five pillars: clinical legitimacy, care quality, transparency, access, and cost. For this page, we compared Ro and Sesame on verified public information rather than giving them new numbers. See our methodology.

Verification date: September 22, 2026. Prices, eligibility, and trial status can change. Use the linked primary sources to check an offer before paying. The dates shown here record this review; they are not a promise that a future price or approval is guaranteed.

Frequently asked questions

The questions below cover timing, dose limits, diabetes, insurance, and access. A different brand name, a different dose, and a different treatment plan are not the same thing.

How long should I give Mounjaro before calling it a failure?

There is no single U.S. label deadline for declaring weight-loss failure. NICE's UK guidance calls for a review if weight loss is below 5% after 6 months at the highest tolerated dose. That means discuss whether to continue—not wait through side effects or automatically stop. Review your prescribed dose history with your clinician. ⁶, ⁷

Is Zepbound stronger than Mounjaro?

No. Both contain tirzepatide. Switching can help with the approved indication, coverage, or access, but the same dose under a new brand name is not a stronger medicine. Zepbound's sleep-apnea approval is specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. ⁶, ¹

Can I go straight from Mounjaro to Wegovy HD?

No. Wegovy HD 7.2 mg is only for adults who have tolerated Wegovy 2.4 mg for at least 4 weeks and need additional weight reduction. You work up through regular Wegovy first, and your prescriber sets your starting dose. Do not use matching milligram numbers to switch between the drugs. ²

Is Wegovy weaker than Mounjaro?

At the doses tested in SURMOUNT-5, average loss was 13.7% with semaglutide versus 20.2% with tirzepatide in adults without diabetes. But an average doesn't predict what will happen to you. Wegovy HD 7.2 mg was not tested in that comparison; its 20.7% result comes from a separate trial's continued-treatment analysis. ³, ¹⁸

Can I take Mounjaro and Wegovy together?

Do not take them as a combined treatment on your own. Wegovy's label does not recommend use with another GLP-1 medicine. When you switch, get your last-dose and first-dose instructions from your prescriber. You don't stack. ²

I'm on 15 mg and still not losing. Can I go higher?

Not within Mounjaro's approved adult dosing. 15 mg once weekly is the adult maximum. "Custom" higher doses are not FDA-approved Mounjaro dosing, and FDA has received reports involving compounded doses and schedules beyond approved labeling. Ask your prescriber for a full review instead. ⁶, ²⁷

Should I take a break to "reset" Mounjaro?

A break is not an established fix for poor response. Stopping treatment can lead to regain: in ATTAIN-MAINTAIN, people switched from tirzepatide to placebo regained about 9.1 kg—20 lb—over 24 weeks on average. Talk to your prescriber before you stop. ³³

When will retatrutide be available?

There is no confirmed FDA-approved retail launch date. As of September 22, 2026, retatrutide is not FDA-approved, and Lilly says it plans to submit an application in the first quarter of 2027. A planned application is not an approval date. Check legitimate clinical trials rather than research-peptide sellers. ²⁵, ²⁷

My blood sugar improved, but my weight didn't. Did Mounjaro fail?

Not necessarily. Blood sugar control and weight loss are two different goals. Mounjaro's current approved uses include blood sugar control and cardiovascular risk reduction in specified patients with type 2 diabetes. Talk with the clinician who manages your diabetes before stopping a medicine that may still be helping your A1C. ⁶

Does Medicare cover my next GLP-1?

Possibly, but the path depends on the diagnosis. The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027, with a $50 copay for qualifying beneficiaries enrolled in eligible Part D plans. It operates outside the usual Part D benefit and payment process and requires prior authorization. ⁴²

CMS includes all listed formulations of Foundayo and Wegovy, including Wegovy HD, plus Zepbound KwikPen—not Zepbound single-dose pens or vials. Eligibility uses BMI at the start of GLP-1 therapy: 35 or above; 30 or above with heart failure with preserved ejection fraction, CMS-defined uncontrolled blood pressure despite two medicines, or chronic kidney disease stage 3a or above; or 27 or above with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. ⁴²

The key point after Mounjaro: CMS says people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH must use the normal Part D coverage path for those indications, not the Bridge, even if they otherwise meet its weight criteria. See the Medicare GLP-1 Bridge guide and CMS's exact eligibility rules before assuming the $50 price applies.

I'm in the UK. Does this apply to me?

Partly. In the UK, Mounjaro itself is licensed for weight management, and prices and programs are different. The studies can inform a discussion with your clinician, but the U.S. products, prices, providers, and coverage programs on this page may not apply. The six-month review point comes from UK NICE guidance. ⁷

Still not sure which GLP-1 program is right for you? Use our matching tool to explore your care options.

Find My GLP-1 Path →

Related reading: Best GLP-1 after failing Wegovy · Best GLP-1 after failing Ozempic · Best Mounjaro alternatives · Best Zepbound alternatives · GLP-1 weight loss plateau · Best Foundayo providers

This page is for information only and is not medical advice. Decisions about starting, stopping, switching, or dosing any medicine should be made with a licensed clinician. We keep FDA-approved and compounded products strictly separate and never treat them as equivalent.

Sources

1. Zepbound prescribing information and medication guide. DailyMed.
2. Wegovy prescribing information, including tablets and Wegovy HD. DailyMed.
3. SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 2025.
4. Case report of semaglutide response after tirzepatide nonresponse. PubMed Central, 2026.
5. Escalate or switch? Treating the post-titration GLP-1 non-responder. medRxiv preprint, July 2026; not peer-reviewed.
6. Mounjaro prescribing information and medication guide, including August 2026 changes. DailyMed.
7. Prescribing, reviewing and stopping tirzepatide. NICE, TA1026 prescribing resource.
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. American Diabetes Association.
9. Weight reduction over time by early weight loss response: SURMOUNT-1 post hoc analysis. Diabetes, Obesity and Metabolism, 2025.
10. ATTAIN-MAINTAIN randomized trial. Nature Medicine, 2026.
11. SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN results. Lilly, May 12, 2026.
12. FDA approval of Foundayo, orforglipron. FDA, April 1, 2026.
13. ATTAIN-1 results and adverse-event data. Lilly's report of the study published in New England Journal of Medicine, 2025.
14. Tirzepatide efficacy by early weight response: SURMOUNT-1 and SURMOUNT-2. Diabetes, Obesity and Metabolism, 2026.
15. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
16. SURMOUNT-2 results published in The Lancet. Lilly's report of the published study, 2023.
17. Time to weight plateau with tirzepatide in SURMOUNT-1 and SURMOUNT-4. Clinical Obesity, 2025.
18. Wegovy HD approval and STEP UP results. Novo Nordisk company announcement, March 19, 2026.
19. NovoCare Wegovy medication and offer information. Checked September 22, 2026.
20. LillyDirect Foundayo pricing. Checked September 22, 2026.
21. Foundayo full offer terms and conditions. Checked September 22, 2026.
22. LillyDirect Zepbound pricing and offer terms. Checked September 22, 2026.
23. CagriSema FDA submission. Novo Nordisk, December 18, 2025.
24. CagriSema REDEFINE 4 head-to-head results. Novo Nordisk company announcement, February 23, 2026.
25. Retatrutide TRIUMPH-2 and TRIUMPH-3 results and planned filing. Lilly, July 23, 2026.
26. Retatrutide TRIUMPH-1 results and safety data. Lilly, June 6, 2026.
27. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA; reviewed September 22, 2026.
28. CagriSema REIMAGINE 5 and REDEFINE 9 update. Novo Nordisk company announcement, September 21, 2026.
29. Ro program and medication pricing. Checked September 22, 2026.
30. Success by Sesame program pricing, features, and medication information. Checked September 22, 2026.
31. Mounjaro FAQ and list-price information. Lilly; checked September 22, 2026.
32. Zepbound full self-pay offer terms and conditions. LillyDirect; checked September 22, 2026.
33. ATTAIN-MAINTAIN results, including matched 24-week regain figures. Lilly, December 18, 2025.
34. REDEFINE 2: Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 2025.
35. Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases.
36. Ro Terms of Use, including Body membership terms. Checked September 22, 2026.
37. Sesame Terms of Service, including cancellation and multi-month refunds. Checked September 22, 2026.
38. Ro company reviews and TrustScore. Trustpilot; retrieved September 22, 2026.
39. Sesame company reviews and TrustScore. Trustpilot; retrieved September 22, 2026.
40. Ro's Mounjaro information and availability statement. Checked September 22, 2026.
41. Ro review page containing the quoted Donna and Audrey reviews. Trustpilot; retrieved September 22, 2026.
42. Medicare GLP-1 Bridge: Information for Providers. CMS; reviewed September 22, 2026.